Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Etiology, Diagnosis, and Management of RV Failure in PH

Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2014 International PHA Conference and Scientific Sessions

Release Date: 03.27.2017

Authors

Raymond Benza, M.D.
Allegheny General Hospital
Pittsburgh, PA. 

Educational Objectives

To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:
  1. Understand the difference in the physiology of the right and left and interventricular interdependence
  2. Learn how to identify RV failure and the basics of RV imaging
  3. Understand the basics of acute RV failure management
  4. Understand the concept of chronic right ventricle support

Intended Audience

This educational activity is intended for;
  1. Non-physician
  2. Nurses
  3. Other
  4. Physicians

Unapproved/Off-Label Use Disclosure

  1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved) 
  2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for educational purposes and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Faculty, Planners, Staff Disclosure Information

All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty and planners of this educational activity disclose the following:
  1. Raymond Benza, M.D., receives grant support from Gilead Sciences, Inc.; United Therapeautics Corporation; Ikaria, Inc.; and GeNO; and is an advisory board member for Bayer HealthCare and a steering committee member for Actelion Pharmaceuticals US, Inc.
  2. PHA and PESG Staff have no relevant financial relationships to disclose.